Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
ICER Released First Cost-Effectiveness Assessment for a Digital Therapeutic (DTx)
Three digital health technologies have been developed to treat opioid use disorder (OUD). These applications, reSET-O (Pear Therapeutics), Connections (Chess Health) and DynamiCare (DynamiCare Health) [...]
Blog
FDA Launches the Digital Health Center of Excellence
Written by Tom Rutkowski, Jay Galli, and Kate Watkins
Blog
CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA
Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site...
Blog
Ten Long-Term Impacts of COVID-19 on Biopharma
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski
Blog
Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake.
Payers are still at very different stages in their acceptance of DTx, and...
Blog
2019 NRDL: Insights for Future Pricing Negotiations in China
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed...
